NCT03103490View on ClinicalTrials.gov

18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation

PHASE2TerminatedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 2, 2017

Primary Completion Date

September 28, 2021

Study Completion Date

September 28, 2021

Conditions
Cardiac SarcoidosisMyocardial Inflammation
Interventions
DRUG

18F-FSPG

Patients receive 8mCi of 18F-FSPG and undergo PET/MRI imaging (or PET/CT for patients with metal implants) to determine the ability of 18F-FSPG to localize to cardiac sarcoidosis or myocardial inflammation.

Trial Locations (1)

94305

Stanford University, Stanford

Sponsors

Collaborators (1)

GE Healthcare
All Listed Sponsors
collaborator

GE Healthcare

INDUSTRY

lead

Stanford University

OTHER